Long-acting insulin compound

A compound, comprising:

• (I) an amino acid sequence set forth in Formula I,
• wherein,
• X1 in Formula I is selected from the group consisting of S, CH2, NH and CO;
• X2 in Formula I is selected from the group consisting of S, CH2, NH and CO;
• AA1 in Formula I is selected from the group consisting of Asp, Glu and Ada;
• AA2 in Formula I is selected from the group consisting of any amino acid for coding other than Cys, and any non-coded amino acid without SH group, or is absent;
• AA3 in Formula I is selected from the group consisting of His, Tyr and Phe;
• AA4 in Formula I is selected from the group consisting of Asp, Glu and Ada;
• AA5 in Formula I is selected from the group consisting of His, Tyr and Phe;
• AA6 in Formula I is selected from the group consisting of any amino acid for coding other than Cys, and any non-coded amino acid without SH group;
• AA7 in Formula I is selected from the group consisting of any amino acid for coding other than Cys, and any non-coded amino acid without SH group;
• AA8 in Formula I is selected from the group consisting of any amino acid for coding other than Cys, and any non-encodable amino acid without SH group;
• AA9 in Formula I is Thr, or is absent;
• AA10 in Formula I is selected from the group consisting of Lys, Dah, Orn, Dab and Dap, or is absent;
• R1 and R2 in Formula I are HO2C(CH2)n1CO-(γGlu)n2-(PEGn3(CH2)n4CO)n5-;
• and
• R1 and R2 in Formula I are not present at the same time;
• (II) an amino acid sequence obtained from substitution, deletion, addition and/or replacement of one or more amino acids of the amino acid sequence set forth in (I);
• or
• (III) a sequence with more than 90% homology to the amino acid sequence set forth in (I) or (II);
• or
• (IV) a pharmaceutically acceptable salt, solvate, chelate or non-covalent complex of the compound set forth in Formula I;
• and/or
• (V) a drug precursor based on the compound shown in Formula I;
• and/or
• (VI) a mixture comprising (I), (II), (III), (IV) and/or (V).